Cellectar Biosciences - CLRB Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLRB shares.
View CLRB analyst ratings or view top-rated stocks.

2 analysts have issued 12-month price targets for Cellectar Biosciences' shares. Their CLRB share price forecasts range from $4.00 to $12.00. On average, they expect the company's stock price to reach $7.67 in the next twelve months. This suggests a possible upside of 338.1% from the stock's current price.
View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts.

Cellectar Biosciences' stock was trading at $6.64 at the beginning of the year. Since then, CLRB shares have decreased by 73.6% and is now trading at $1.75.
View the best growth stocks for 2022 here.

Cellectar Biosciences saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 8,100 shares, a decrease of 16.5% from the October 31st total of 9,700 shares. Based on an average daily volume of 36,400 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.1% of the company's stock are short sold.
View Cellectar Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 20th 2023.
View our CLRB earnings forecast.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) announced its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.10.

Cellectar Biosciences's stock reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Cellectar Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.87%), BlackRock Inc. (0.61%), Worth Venture Partners LLC (0.44%), Maven Securities LTD (0.27%), Maven Securities LTD (0.27%) and ACT Capital Management LLC (0.36%). Insiders that own company stock include Dov Elefant, James V Caruso, Jarrod Longcor and Stephen A Hill.
View institutional ownership trends.

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLRB stock can currently be purchased for approximately $1.75.

Cellectar Biosciences (NASDAQ:CLRB) has a market capitalization of $16.42 million. The biopharmaceutical company earns $-24,120,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis.

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The official website for the company is www.cellectar.com. The biopharmaceutical company can be reached via phone at (608) 441-8120, via email at ir@cellectar.com, or via fax at 608-441-8121.